| Etanercept - When and when not? - An overview (2005) | |||||||||||||
Abstract | |||||||||||||
| Etanercept was licensed in Europe in 2000 for special forms of juvenile idiopathic arthritis (JIA), and has greatly increased therapeutic options. Nearly 80% of all patients with polyarticular JIA show impressive therapeutic results. Short-to medium term observed adverse drug reactions are manageable. Etanercept is currently licensed only for children of over 4 years of age with polyarticular JIA that failed to respond to methotrexate. Licensed usage is expected to be extended in the near future. Etanercept should only be prescribed by an experienced pediatric rheumatologist. To date there are no recommendations as to when the treatment with etanercept may be stopped once the patient goes into remission. Follow-up is required to exclude long term adverse drug reactions. | |||||||||||||
Details der Publikation | |||||||||||||
| |||||||||||||